Advertisement

Diabetologia

, Volume 61, Issue 5, pp 1237–1237 | Cite as

Correction to: Chronomedicine and type 2 diabetes: shining some light on melatonin

  • Andrew C. Forrestel
  • Susanne U. Miedlich
  • Michael Yurcheshen
  • Steven D. Wittlin
  • Michael T. Sellix
Correction
  • 1.1k Downloads

Correction to: Diabetologia

 https://doi.org/10.1007/s00125-016-4175-1

The authors have been made aware that the following sentence is incorrect: ‘Like IIK7, both ramelteon and tasimelteon have a greater affinity for the MT2 receptor.’ In fact, ramelteon has a greater affinity for MT1 than MT2, whereas tasimelteon, like IIK7, preferentially binds to the MT2 receptor [1]. The authors apologise for this error.

Reference

  1. 1.
    Williams WP III, McLin DE III, Dressman MA, Neubauer DN (2016) Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. Pharmacotherapy 36:1028–1041CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Andrew C. Forrestel
    • 1
  • Susanne U. Miedlich
    • 1
  • Michael Yurcheshen
    • 2
  • Steven D. Wittlin
    • 1
  • Michael T. Sellix
    • 1
  1. 1.Division of Endocrinology, Diabetes and Metabolism, Department of MedicineUniversity of Rochester School of Medicine and DentistryRochesterUSA
  2. 2.UR Medicine Sleep Center, Department of NeurologyUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations